Supportive care in pancreatic ductal adenocarcinoma

被引:0
|
作者
B. Laquente
A. Calsina-Berna
A. Carmona-Bayonas
P. Jiménez-Fonseca
I. Peiró
A. Carrato
机构
[1] Instituto Catalán de Oncología,Department Medical Oncology
[2] Hospital Germans Trias I Pujol,Department Palliative Care
[3] Instituto Catalán de Oncología,Department Medical Oncology and Hematology
[4] Hospital Universitario Morales Meseguer,Department Medical Oncology
[5] Hospital Universitario Central de Asturias,Clinical Nutrition Unit
[6] Instituto Catalán de Oncología,Department Medical Oncology
[7] Hospital Universitario Ramón y Cajal,undefined
来源
Clinical and Translational Oncology | 2017年 / 19卷
关键词
Supportive care; Pancreatic ductal adenocarcinoma; Symptoms; Biliary obstruction; Cachexia; Thromboembolic disease;
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy. Symptomatic management should be accomplished in a multidisciplinary fashion. Its primary aims include relief of biliary or duodenal obstruction, prevention and/or treatment of thromboembolic disease, and control cancer-related pain. Nutritional support and optimal replacement therapy in patients with endocrine and/or exocrine insufficiency, is mandatory. This manuscript highlights the most significant problems faced when caring for patients with advanced PDAC and provides an evidence-based approach to symptomatic management.
引用
收藏
页码:1293 / 1302
页数:9
相关论文
共 50 条
  • [21] Biomarkers in pancreatic ductal adenocarcinoma
    Gallego, J.
    Lopez, C.
    Pazo-Cid, R.
    Lopez-Rios, F.
    Carrato, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12): : 1430 - 1437
  • [22] Desmoplasia of Pancreatic Ductal Adenocarcinoma
    Pandol, Stephen
    Edderkaoui, Mouad
    Gukovsky, Ilya
    Lugea, Aurelia
    Gukovskaya, Anna
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (11) : S44 - S47
  • [23] Models of pancreatic ductal adenocarcinoma
    Rayane Dennaoui
    Hridaya Shrestha
    Kay-Uwe Wagner
    Cancer and Metastasis Reviews, 2021, 40 : 803 - 818
  • [24] Carcinogenesis of Pancreatic Ductal Adenocarcinoma
    Storz, Peter
    Crawford, Howard C.
    GASTROENTEROLOGY, 2020, 158 (08) : 2072 - 2081
  • [25] Genomics of pancreatic ductal adenocarcinoma
    Pilarsky, Christian
    Gruetzmann, Robert
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2014, 13 (04) : 381 - 385
  • [26] Genomics of pancreatic ductal adenocarcinoma
    Christian Pilarsky
    Robert Grützmann
    Hepatobiliary & Pancreatic Diseases International, 2014, 13 (04) : 381 - 385
  • [27] Familial Pancreatic Ductal Adenocarcinoma
    Diaz, Kelly E.
    Lucas, Aimee L.
    AMERICAN JOURNAL OF PATHOLOGY, 2019, 189 (01): : 36 - 43
  • [28] MicroRNAs in pancreatic ductal adenocarcinoma
    Jong Y Park
    James Helm
    Domenico Coppola
    Donghwa Kim
    Mokenge Malafa
    Seung Joon Kim
    World Journal of Gastroenterology, 2011, 17 (07) : 817 - 827
  • [29] Pancreatic ductal adenocarcinoma staging
    Al-Hawary, Mahmoud M.
    Francis, Isaac R.
    CANCER IMAGING, 2013, 13 (03): : 360 - 364
  • [30] Mimics of pancreatic ductal adenocarcinoma
    Al-Hawary, Mahmoud M.
    Kaza, Ravi K.
    Azar, Shadi F.
    Ruma, Julie A.
    Francis, Isaac R.
    CANCER IMAGING, 2013, 13 (03) : 342 - 349